Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates

This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n =156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n =60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P =0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P =0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.